NEW HAVEN, Conn. -- Aug. 31, 2026 -- Yale School of Medicine has secured a nearly $25 million grant from the Aligning Research to Impact Autism (ARIA) initiative to build the first high-resolution map of the developing human brain and pinpoint where autism diverges from typical neural development.

MUNICH, Germany -- August 31, 2026 -- Amgen's Repatha (evolocumab) reduced all-cause mortality by 20% in high-risk patients who had never suffered a heart attack or stroke, according to a pre-specified analysis of the Phase 3 VESALIUS-CV trial presented at the European Society of Cardiology Congress 2026 and published simultaneously in Circulation.

THOUSAND OAKS, Calif. -- September 01, 2026 -- Amgen said its cholesterol drug Repatha reduced the risk of death by 20% among more than 12,000 high-risk adults who had not yet suffered a heart attack or stroke, based on a pre-specified analysis of the Phase 3 VESALIUS-CV trial. The company presented the data in a late-breaking session at the European Society of Cardiology Congress 2026 in Munich, Germany, and published the findings simultaneously in Circulation.

Incheon, South Korea and Zug, Switzerland -- Samsung Biologics, through its Swiss subsidiary Samsung Peptide AG, published the formal tender offer prospectus for PolyPeptide Group AG, setting a cash price of CHF 44.31 per share and an implied equity value of approximately CHF 1.46 billion. The filing, made in Zug, Switzerland, follows a pre-announcement issued July 20, 2026, and covers all publicly held shares of the peptide-focused contract manufacturer listed on the SIX Swiss Exchange. The main acceptance period runs from Sept. 15 to Oct. 12, 2026.

MASON, Ohio -- September 01, 2026 -- Prasco, LLC has acquired a 130,000-plus square foot distribution facility in Carey, Ohio, expanding the pharmaceutical commercialization company's automation, cold-chain and secure storage capacity beyond its existing Mason, Ohio operations. The deal, announced Aug. 31, 2026, adds a second Ohio campus for the company, which works with more than 65 brand partners and supplies medications to over 70,000 pharmacies nationwide. Prasco specializes in Authorized Generics and end-to-end commercialization services for global drug brands.

CARY, N.C. -- September 01, 2026 -- Veloxis Pharmaceuticals dosed the first participant on Aug. 31, 2026, in its Phase 2 RENGEVITY-201 trial testing pegrizeprument, an investigational immunosuppressive drug, against tacrolimus in kidney transplant recipients. The Cary, North Carolina-based company, a unit of Asahi Kasei Corporation, will enroll up to 120 de novo kidney transplant patients across multiple sites in the randomized, partially blinded study registered as NCT07290777.

INDIANAPOLIS and CAMBRIDGE, Mass. -- Aug. 31, 2026 -- Eli Lilly and Company agreed to pay up to $2.875 billion in cash to acquire Merida Biosciences, a Cambridge, Massachusetts-based biotechnology company developing antibody-degrading therapies for autoimmune and allergic diseases. The figure includes an upfront payment plus contingent milestone payments under a definitive agreement announced by both companies. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026.

SOUTH SAN FRANCISCO, Calif. -- September 01, 2026 -- IDEAYA Biosciences said its FDA Type C meeting on IDE849, a DLL3-targeting antibody drug conjugate, produced agreement on a Phase 3 registrational trial design for extensive stage small cell lung cancer (ES-SCLC). The Nasdaq-listed company (IDYA) plans to enroll roughly 400 patients who have already received tarlatamab, randomizing them 1:1 between IDE849 monotherapy and an investigator's choice control arm of topotecan and amrubicin. IDEAYA is targeting trial initiation by year-end 2026.